Stifel analyst David Grossman raised the firm’s price target on Amwell (AMWL) to $10 from $9 and keeps a Hold rating on the shares. 2025 guidance implies adjusted revenue growth of 8%-12% ex-APC divestiture and lower operating losses, notes the analyst, who is rolling forward the firm’s price target to 2026 estimates.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMWL:
- Strong Revenue Performance and Strategic Growth: Justifying the Buy Rating for American Well
- Hold Rating for American Well Amid Mixed Financial Outlook and Strategic Shifts
- Amwell Reports Improved 2024 Financial Results
- American Well: Navigating Challenges with Resilience and Future Growth Potential
- Amwell sees Q1 revenue $59M-$61M, consensus $74.31M